Klinik für Urologie - Lehrstuhl der Universität Regensburg

Publikationen

Publikationen zur experimentellen Urologie aus unserer Klinik seit der Gründung 2003

Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer. Fransen van de Putte EE, Otto W, Hartmann A, Bertz S, Mayr R, Bründl J, Breyer J, Manach Q, Compérat EM, Boormans JL, Bosschieter J, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Burger M, van der Kwast TH, van Rhijn BWG. Urol Oncol. 2018 Jun 4. pii: S1078-1439(18)30159-5. doi: 10.1016/j.urolonc.2018.05.007.

The WHO 1973 classification system for grade is an Important prognosticator in T1 non-muscle-invasive bladder cancer. Fransen van de Putte EE, Bosschieter J, van der Kwast TH, Bertz S, Denzinger S, Manach Q, Compérat EM, Boormans JL, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Otto W, Burger M, Hartmann A, van Rhijn BWG.BJU Int. 2018 Apr 10. doi: 10.1111/bju.14238.

High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma. Breyer J, Wirtz RM, Erben P, Worst TS, Stoehr R, Eckstein M, Bertz S, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W. Clin Genitourin Cancer. 2018 Feb 2. pii: S1558-7673(18)30036-3. doi: 10.1016/j.clgc.2018.01.009.

Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naïve stage T1 high-grade urothelial bladder cancer. Otto W, van Rhijn BW, Breyer J, Bertz S, Eckstein M, Mayr R, Lausenmeyer EM, Denzinger S, Burger M, Hartmann A. Int J Urol. 2018 Feb 22.

A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W, Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P. Oncotarget. 2018 Feb 19;9(19):15001-15014.

Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer. Kriegmair MC, Wirtz RM, Worst TS, Breyer J, Ritter M, Keck B, Boehmer C, Otto W, Eckstein M, Weis CA, Hartmann A, Bolenz C, Erben P. Transl Oncol. 2018 Feb 22;11(2):467-476.

Differentiation-associated urothelial cytochrome P450 oxidoreductase predicates the xenobiotic-metabolizing activity of "luminal" muscle-invasive bladder cancers. Baker SC, Arlt VM, Indra R, Joel M, Stiborová M, Eardley I, Ahmad N, Otto W, Burger M, Rubenwolf P, Phillips DH, Southgate J. Mol Carcinog. 2018 Jan 11. doi: 10.1002/mc.22784.

p53-expression in patients with renal cell carcinoma correlates with a higher probability of disease progression and increased cancer-specific mortality after surgery but does not enhance the predictive accuracy of robust outcome models. Morshaeuser L, May M, Burger M, Otto W, Hutterer GC, Pichler M, Klatte T, Wild P, Buser L, Brookman-May S. Urol Oncol. 2018 Mar;36(3):94.e15-94.e21.

High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. Breyer J, Wirtz RM, Otto W, Erben P, Worst TS, Stoehr R, Eckstein M, Denzinger S, Burger M, Hartmann A. Cancer Immunol Immunother. 2018 Mar;67(3):403-412.

Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies. Breyer J, Wirtz RM, Otto W, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A. Oncotarget. 2017 Jun 28;8(40):67684-67695.

FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes. Rinaldetti S, Wirtz RM, Worst TS, Eckstein M, Weiss CA, Breyer J, Otto W, Bolenz C, Hartmann A, Erben P. Oncotarget. 2017 Jul 18;8(29):47595-47606.

[Clinical and pathological prognostic factors for the long-term survival of patients with pT1 renal cell carcinoma]. Breyer J, Otto W, Lausenmeyer EM, Denzinger S, Schwientek AK, Ochs L, Mayr R, Gierth M, Bründl J, Burger M, Evert M, Fritsche HM, Eichelberg C. Aktuelle Urol. 2017 May;48(3):230-237.

Aquaporin 3 Expression Loss in Urothelial Carcinoma: Association with Tumor Invasion Depth, but not with Grading? Breyer J, Otto W, Burger M, Hartmann A, Rubenwolf PC. Bladder Cancer. 2017 Jan 27;3(1):31-34.

In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. Breyer J, Wirtz RM, Otto W, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Eidt S, Denzinger S, Burger M, Hartmann A; BRIDGE Consortium. Virchows Arch. 2017 Mar;470(3):267-274

ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ. Breyer J, Otto W, Wirtz RM, Wullich B, Keck B, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Laible M, Schlombs K, Eidt S, Denzinger S, Burger M, Hartmann A; BRIDGE Consortium. Urol Int. 2017;98(3):282-289.

Increased Proliferation as Independent Predictor of Disease Recurrence in Initial Stage pTa Urothelial Bladder Cancer. Breyer J, Shalekenov S, AzizA, van RhijnBWG, Bründl J, LausenmeyerE, Schäfer J, Denzinger S, GiedlC, Burger M, HartmannA, EvertM, Otto W. Bladder Cancer. 2017 Jul 27;3(3):173-180.

High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer. Sikic D, Breyer J, Hartmann A, Burger M, Erben P, Denzinger S, Eckstein M, Stöhr R, Wach S, Wullich B, Keck B, Wirtz RM, Otto W. Transl Oncol. 2017 Jun;10(3):340-345.

WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach. Otto W, Breyer J, Herdegen S, Eder F, Bertz S, May M, Mayr R, Lausenmeyer EM, Denzinger S, van Rhijn BW, Burger M, Hartmann A. Int Urol Nephrol. 2017 Mar;49(3):431-437.

Immunotherapy in urothelial carcinoma: fade or future standard? Breyer J, Burger M, Otto W. Transl Androl Urol. 2016 Oct;5(5):662-667.

ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC). Breyer J, Wirtz RM, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A, Otto W. Virchows Arch. 2016 Nov;469(5):547-552.

Downregulation of Checkpoint Protein Kinase 2 in the Urothelium of Healthy Male Tobacco Smokers. Breyer J, Denzinger S, Hartmann A, Otto W. Urol Int. 2016;97(4):480-481.

Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma. Breyer J, Gierth M, Shalekenov S, Aziz A, Schäfer J, Burger M, Denzinger S, Hofstädter F, Giedl C, Otto W. World J Urol. 2015 Sep 22.

A switch from epithelial to mesenchymal properties correlates with lymphovascular invasion in squamous cell carcinoma of the penis. May M, Brookman-May S, Burger M, Koch S, Otto W, Bründl J, Albrecht K, Denzinger S. Pathol Res Pract. 2015 Sep;211(9):641-5

Loss of AQP3 protein expression is associated with worse progression-free and cancer-specific survival in patients with muscle-invasive bladder cancer. Rubenwolf P, Thomas C, Denzinger S, Hartmann A, Burger M, Georgopoulos NT, Otto W. World J Urol. 2015 May 5.

Anatomical Study of Pelvic Nerves in Relation to Seminal Vesicles, Prostate and Urethral Sphincter: Immunohistochemical Staining, Computerized Planimetry and 3-Dimensional Reconstruction. Ganzer R, Stolzenburg JU, Neuhaus J, Weber F, Fuchshofer R, Burger M, Bründl J. J Urol. 2015 Apr;193(4):1205-12

Computerized quantification and planimetry of prostatic capsular nerves in relation to adjacent prostate cancer foci.
 Bründl J, Schneider S, Weber F, Zeman F, Wieland WF, Ganzer R. Eur Urol. 2014;65(4): 802-8

Epigenetic inactivation of ITIH5 promotes bladder cancer progression and predicts early relapse of pT1 high-grade urothelial tumours.
Rose M, Gaisa NT, Antony P, Fiedler D, Heidenreich A, Otto W, Denzinger S, Bertz S, Hartmann A, Karl A, Knüchel R, Dahl E. Carcinogenesis. 2014;35(3): 727-36

Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
Bertz S, Otto W, Denzinger S, Wieland WF, Burger M, Stöhr R, Link S, Hofstädter F, Hartmann A. Eur Urol. 2014;65(1): 218-26

Diagnostic and prognostic impact of peritumoral stromal remodeling in patients with surgically treated invasive penile squamous cell cancer.
Gunia S, Jain A, Albrecht K, Koch S, Otto W, Denzinger S, Götz S, Niessl N, Burger M, May M. Hum Pathol. 2014;45(6): 1169-76

Outcome of patients with pathological tumor stage T3 urothelial carcinoma of the bladder following radical cystectomy in a single-center series with 116 patients.
Breyer J, Denzinger S, Otto W, Bründl J, Gierth M, Fritsche HM, Rößler W, Wieland WF, Giedl C, Hofstädter F, Rubenwolf P, Burger M, Aziz A. Urol Int. 2014;93(3): 311-9

Is the striated urethral sphincter at risk by standard suture ligation of the dorsal vascular complex in radical prostatectomy? An anatomic study.
Ganzer R, Stolzenburg JU, Neuhaus J, Weber F, Burger M, Bründl J. Urology. 2014;84(6): 1453-60

Expression of aquaporin water channels in human urothelial carcinoma: correlation of AQP3 expression with tumour grade and stage.
Rubenwolf PC, Otto W, Denzinger S, Hofstädter F, Wieland W, Georgopoulos NT. World J Urol. 2014;32(4): 991-7

Ki-67, mini-chromosome maintenance 2 protein (MCM2) and geminin have no independent prognostic relevance for cancer-specific survival in surgically treated squamous cell carcinoma of the penis. May M, Burger M, Otto W, Hakenberg OW, Wieland WF, May D, Hofstädter F, Götz S, Niessl N, Fritsche HM, Birnkammer K, Gilfrich C, Peter J, Jain A, Koch S, Lebentrau S, Riedmiller H, Rössler W, Denzinger S, Brookman-May S, Gunia S. BJU Int. 2013;112(4): E383-90

Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three hundred six patients.
Otto W, Denzinger S, Fritsche HM, Burger M, Rößler W, Bertz S, May M, Hartmann A, Hofstädter F, Wieland WF, Eder F. Clin Genitourin Cancer. 2013; Dec;11(4):537-44

Persistent histological changes in the exstrophic bladder after primary closure-a cause for concern? Rubenwolf PC, Eder F, Ebert AK, Hofstaedter F, Woodhouse CR, Roesch WH. J Urol. 2013;189(2): 671-7 


Anatomic study of periprostatic nerve distribution: immunohistochemical differentiation of parasympathetic and sympathetic nerve fibres. Ganzer R., Stolzenburg JU, Wieland F
WF, Bründl J. Eur Urol. 2012;62(6): 1150-6

Loss of aquaporin 3 protein expression constitutes an independent prognostic factor for progression-free survival: an immunohistochemical study on stage pT1 urothelial bladder cancer.
Otto W, Rubenwolf PC, Burger M, Fritsche HM, Rößler W, May M, Hartmann A, Hofstädter F, Wieland WF, Denzinger S. BMC Cancer. 2012;12(1): 459

Aquaporin 3 protein expression in transitional cell carcinoma: a potential marker with regard to tumour progression and prognosis?
Rubenwolf PC, Denzinger S, Otto W. Eur Urol. 2012;61(3): 627-8

Immunohistochemical marker panel differentiates between the three most common subtypes of renal cell carcinoma independent from histomorphologic criteria.
Walter B, Hartmann A, Hofstädter F, Junker K, Moch H, Bertz S, Denzinger S, Otto W, Gajda M, Stoehr CG. Virchows Arch. 2012;460(3): 343-52

First analysis of immune cell infiltration in stage pT1 urothelial bladder carcinoma: CD3 positivity as a prognostic marker for cancer-specific survival.
Otto W, Denzinger S, Wieland WF, Hartmann A. World J Urol. 2012;30(6): 875-7

Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series.
Bertz S, Otto W, Wieland WF, Stoehr R, Hofstaedter F, Denzinger S, Hartmann A.
Histopathology. 2011 Oct;59(4):722-32

Serine threonine kinase 15 amplification in normal urothelium of cystectomy specimens is no prognostic factor in urothelial carcinoma of the bladder.
Otto W, Fritsche HM, Wild PJ, Wieland WF, Hartmann A, Burger M, Hofstädter F, Denzinger S.
Pathol Res Pract. 2011 Mar 15;207(3):161-3

The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer.
Otto W, Denzinger S, Fritsche HM, Burger M, Wieland WF, Hofstädter F, Hartmann A, Bertz S.
BJU Int. 2011 Feb;107(3):404-8

DNA adducts of ortho-toluidine in human bladder.
Böhm F, Schmid D, Denzinger S, Wieland WF, Richter E.
Biomarkers. 2011 Mar;16(2):120-8

Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma?
Brookman-May S, May M, Gilfrich C, Wieland WF, Burger M.
Expert Rev Anticancer Ther. 2010;10(6): 813-23

Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder.
Fritsche HM, Burger M, Dietmaier W, Denzinger S, Bach E, Otto W, Doblinger M, Schwarz S, Buchner H, Hartmann A.
Am J Clin Pathol. 2010;134(4): 597-603

Ongoing outbreak of mumps affecting adolescents and young adults inBavaria,Germany, August to October 2010.
Otto W, Mankertz A, Santibanez S, Saygili H, Wenzel J, Jilg W, Wieland W, Borgmann S.
Euro Surveill. 2010;15(50)

The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression.
Catto JW, Abbod MF, Wild PJ, Linkens DA, Pilarsky C, Rehman I, Rosario DJ, Denzinger S, Burger M, Stoehr R, Knuechel R, Hartmann A, Hamdy FC.
Eur Urol. 2010;57(3): 398-406

Mutational activation of FGFR3 is not involved in the development of prostate cancer.
Koufou S, Lunz JC, Borchardt A, Keck B, Kneitz B, Gaisa NT, Hafner C, Giedl C, Rau TT, Rogler A, Wieland WF, Hartmann A, Stoehr R.
Pathobiology. 2010;77(5): 249-52

Prognostic value of histopathological tumour growth patterns at the invasion front of T1G3 urothelial carcinoma of the bladder.
Denzinger S, Burger M, Fritsche HM, Bertz S, Hofstädter F, Wieland WF, Hartmann A, Otto W.
Scand J Urol Nephrol. 2009;43(4):282-7

Nerve quantification and computerized planimetry to evaluate periprostatic nerve distribution-does size matter?
Ganzer R, Blana A, Stolzenburg JU, Rabenalt R, Fritsche HM, Wieland WF, Denzinger S.
Urology. 2009 Aug;74(2):398-403
Anatomical description of the periprostatic nerves in the male rhesus monkey (Macaca mulatta).
Ganzer R, Neuhaus J, Gratzke C, Blana A, Wieland WF, Stolzenburg JU.
World J Urol. 2011 Jun;29(3):375-80

No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
Otto W, Denzinger S, Bertz S, Gaumann A, Wild PJ, Hartmann A, Stoehr R.
Int J Cancer. 2009 Nov 1;125(9):2205-8

Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics. Stoehr R, Hitzenbichler F, Kneitz B, Hammerschmied CG, Burger M, Tannapfel A, Hartmann A.
Br J Cancer. 2008 Jul 8;99(1):78-82

Topographical anatomy of periprostatic and capsular nerves: quantification and computerised planimetry.
 Ganzer R, Blana A, Gaumann A, Stolzenburg JU, Rabenalt R, Bach T, Wieland WF, Denzinger S. Eur Urol. 2008 Aug;54(2):353-61

Pax-5 protein expression in bladder cancer: a preliminary study that shows no correlation to grade, stage or clinical outcome.
 Denzinger S, Burger M, Hammerschmied CG, Wieland WF, Hartmann A, Obermann EC, Stoehr R.
Pathology. 2008 Aug;40(5):465-9

Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.
Burger M, van der Aa MN, van Oers JM, Brinkmann A, van der Kwast TH, Steyerberg EC, Stoehr R, Kirkels WJ, Denzinger S, Wild PJ, Wieland WF, Hofstaedter F, Hartmann A, Zwarthoff EC.
Eur Urol. 2008 Oct;54(4):835-43

Role of the STK15 Phe31Ile polymorphism in renal cell carcinoma.
Hammerschmied CG, Stoehr R, Walter B, Wieland WF, Hartmann A, Blaszyk H, Denzinger S.
Oncol Rep. 2007 Jan;17(1):3-7

Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade.
Burger M, Denzinger S, Hartmann A, Wieland WF, Stoehr R, Obermann EC.
Br J Cancer. 2007 Jun 4;96(11):1711-5

FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
 van Oers JM, Wild PJ, Burger M, Denzinger S, Stoehr R, Rosskopf E, Hofstaedter F, Steyerberg EW, Klinkhammer-Schalke M, Zwarthoff EC, van der Kwast TH, Hartmann A.
Eur Urol. 2007 Sep;52(3):760-8

Low level STK15 amplification in histologically benign urothelium of patients with bladder cancer adversely predicts patient outcome following cystectomy.
 Denzinger S, Stoehr R, Schwarz S, Eichenseher N, Brockhoff G, Obermann EC, Knuechel R, Blaszyk H, Hartmann A, Wild PJ.
Int J Oncol. 2007 Oct;31(4):793-802

Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses.
 Denzinger S, Mohren K, Knuechel R, Wild PJ, Burger M, Wieland WF, Hartmann A, Stoehr R.
Hum Pathol. 2006 Feb;37(2):143-51

Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. van Oers JM, Adam C, Denzinger S, Stoehr R, Bertz S, Zaak D, Stief C, Hofstaedter F, Zwarthoff EC, van der Kwast TH, Knuechel R, Hartmann A.

Int J Cancer. 2006 Sep 1;119(5):1212-5

Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer.
Burger M, Denzinger S, Hammerschmied CG, Tannapfel A, Obermann EC, Wieland WF, Hartmann A, Stoehr R.
J Mol Med. 2006 Oct;84(10):833-41

Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations. Burger M, Denzinger S, Hammerschmied C, Tannapfel A, Maderstorfer A, Wieland WF, Hartmann A, Stoehr R. Eur Urol. 2006 Nov;50(5):1102-9; discussion 1109-10

Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer.
 Stoehr R, Zietz S, Burger M, Filbeck T, Denzinger S, Obermann EC, Hammerschmied C, Wieland WF, Knuechel R, Hartmann A.
Eur Urol. 2005 Jan;47(1):58-63

Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses. Denzinger S, Mohren K, Knuechel R, Wild PJ, Burger M, Wieland WF, Hartmann A, Stoehr R. Hum Pathol. 2006 Feb;37(2):143-51

Fluorescence in situ hybridization detects frequent chromosome 9 deletions and aneuploidy in histologically normal urothelium of bladder cancer patients. Obermann EC, Meyer S, Hellge D, Zaak D, Filbeck T, Stoehr R, Hofstaedter F, Hartmann A, Knuechel R. Oncol Rep. 2004 Apr;11(4):745-51

No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract. Stoehr R, Brinkmann A, Filbeck T, Gamper C, Wild P, Blaszyk H, Hofstaedter F, Knuechel R, Hartmann A. Oncol Rep. 2004 Jan;11(1):137-41

Kontaktieren Sie uns

Caritas-Krankenhaus
St. Josef
Klinik für Urologie
Landshuter Straße 65
93053 Regensburg

Hochschulambulanz Urologie
Tel: 0941 782-3511 (Terminvereinbarung für alle Sprechstunden, Befundanforderungen)
Fax: 0941 782-3545

uro-ambulanz@caritasstjosef.de

Sekretariat der Klinik


Helga Hollweck


Sabine Pernpeintner


Tel: 0941 782-3510
Fax: 0941 782-3515

urologie@caritasstjosef.de

Kontakt Anfahrt Seite drucken© 2002-2017 Caritas-Krankenhaus St. Josef | Impressum | Datenschutz | Sitemap | Design & Programmmierung